Global Search | Novartis United States of America

Hide Filters

Showing 683 results

Media Release / Dec 06, 2023

Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH

Approval based on APPLY-PNH trial in adults with PNH and anemia despite prior anti-C5 treatment, and supported by the APPOINT-PNH study in complement inhibitor-naïve patients1-5 In APPLY-PNH…
Media Release / Nov 24, 2023

Novartis Issues Voluntary US Nationwide Recall of Two Lots of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Company Contact: Novartis Pharmaceuticals Corporation 1-888-669-6682 Novartis Media Relations E-mail: [email protected] North America Julie Masow …
Media Release / Oct 31, 2023

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A…
Media Release / Oct 26, 2023

Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers

US FDA has classified drug shortage status as resolved1Novartis capacity to produce Pluvicto will continue to grow with anticipated expansions to the manufacturing network in the US and globally…
Media Release / Oct 23, 2023

Novartis Pluvicto® shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting

Phase III PSMAfore trial with Pluvicto® met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per…
Media Release / Oct 06, 2023

FDA approves Novartis Cosentyx® as first intravenous (IV) formulation interleukin-17A antagonist for rheumatic diseases

First new intravenous (IV) treatment option in six years for adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA)1-6 Cosentyx…
Media Release / Sep 11, 2023

Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Company Contact: Novartis Pharmaceuticals Corporation 1-888-669-6682 EAST HANOVER, N.J., Sept. 11, 2023 -- Novartis is conducting a voluntary nationwide recall at the consumer level of one lot…
Media Release / Aug 28, 2023

Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years

Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-–C) reduction beyond six…
Media Release / Jul 12, 2023

Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers

Advarra, Virb and BeeKeeperAI sign on to Beacon of Hope to provide suite of digital tools to facilitate clinical trials and research on healthcare inequities at Historically Black Medical School…
Media Release / Jul 10, 2023

US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease

Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1 Leqvio can now be used earlier in LDL-C treatment as an adjunct to…

‹ Previous page
1
…
4
5
6
7
8
9
10
…
69
› Next page

Related News & Media